glp-1 agonist fda approval GLP-1R agonists approved by the United States and international GLP-1 Agonists Approved by the
Description
The WHO recommends lower cutoffs for Asian populations: obesity at BMI 27.5 (versus 30 standard) and overweight at BMI 23 (versus 25 standard)
Shi L, Ji Y, Jiang X, Zhou L, Xu Y, Li Y, et al
Both medications slow gastric emptying, but tirzepatide typically causes more pronounced GI effects
Yang BR, Cha SH, Lee KE, Kim JW, Lee J, Shin KH
Common side effects of GLP-1s are gastrointestinal issues, including nausea, vomiting, diarrhea, dehydration, and constipation
